Medical therapy for NLPHL: tradition vs biology. The key question is whether to treat with Hodgkin lymphoma–directed therapy (left) or as an indolent B-cell lymphoma (right). BEACOPDac, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; BrECADD, brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone; BV-AVD, brentuximab vedotin plus doxorubicin (Adriamycin), vinblastine, and dacarbazine; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Professional illustration by Patrick Lane, ScEYEnce Studios.